HMOX1 and osteosarcoma: reported that EF24 could dose-dependently reduce GPX4 expression while releasing intracellular iron to promote ferroptosis in osteosarcoma by upregulating HMOX1 expression, which potentially serves as a therapeutic option for patients with HMOX1-positive osteosarcoma (76).